Table 1 Baseline characteristics and prevalence of thyroid abnormalities

Diagnosis

Leukemia/MDS

45 (17.5%)

30 (20.0%)

15 (14.0%)

< 0.0001

HD

9 (3.5%)

3 (2.0%)

6 (5.6%)

NHL

21 (8.2%)

19 (12.7%)

2 (1.9%)

Brain tumor

85 (33.1%)

36 (24.0%)

49 (45.8%)

Nasopharyngeal ca

3 (1.2%)

0 (0%)

3 (2.8%)

Other

94 (36.6%)

62 (41.3%)

32 (29.9%)

Gender

Male

147 (57.2%)

85 (56.7%)

62 (57.9%)

0.8384

Female

110 (42.8%)

65 (43.3%)

45 (42.1%)

Age at diagnosis, yrs

Mean ± SD

10.7 ± 5.3

10.9 ± 5.4

10.5 ± 5.2

0.5947

Median (Min-max)

11.8 (0.1–19.8)

12.0 (0.4–19.8)

11.2 (0.1–19.3)

Time from completion of therapy

Median (Min-max)

9.6 (5.0–19.5)

9.7 (5.0–19.5)

9.3 (5.0–16.7)

0.2324

Time from diagnosis, yrs

Median (Min-max)

11.2 (5.4–29.5)

11.2 (5.4–29.5)

11.0 (5.5–19.8)

0.8876

Chemotherapy only

No

135 (52.5%)

61 (40.7%)

74 (69.2%)

< 0.0001

Yes

122 (47.5%)

89 (59.3%)

33 (30.8%)

SCT

No

214 (83.3%)

133 (88.7%)

81 (75.7%)

0.0069

Yes

43 (16.7%)

17 (11.3%)

26 (24.3%)

Irradiation group 1

No

144 (56%)

103 (68.7%)

41 (38.3%)

<.0001

Yes

113 (44%)

47 (31.3%)

66 (61.7%)

CSI

No

210 (81.7%)

135 (90%)

75 (70.1%)

< 0.0001

Yes

47 (18.3%)

15 (10%)

32 (29.9%)

Cranial and head

No

221 (86%)

129 (86%)

92 (86%)

0.9966

Yes

36 (14%)

21 (14%)

15 (14%)

Spinal

No

252 (98.1%)

147 (98.0%)

105 (98.1%)

0.9403

Yes

5 (1.9%)

3 (2.0%)

2 (1.9%)

TBI

No

248 (96.5%)

148 (98.7%)

100 (93.5%)

0.0365

Yes

9 (3.5%)

2 (1.3%)

7 (6.5%)

Neck, nasopharynx

No

245 (95.3%)

146 (97.3%)

99 (92.5%)

0.0716

Yes

12 (4.7%)

4 (2.7%)

8 (7.5%)

Irradiation group 2 (Abdomen/pelvis/limbs)

No

235 (91.4%)

136 (90.7%)

99 (92.5%)

0.6572

Yes

22 (8.6%)

14 (9.3%)

8 (7.5%)